Semaglutide & Tirzepatide: First-Line Obesity Treatment

Semaglutide & Tirzepatide: First-Line Obesity Treatment

October 4, 2025 Dr. Jennifer Chen Health

Okay, here’s a breakdown of the key facts from the provided text, focusing on the recommendations for obesity treatment and related considerations:

Key Takeaways: EASO Obesity Treatment Framework

* Incretin-Based Therapies are Cornerstone: The European Association for the Study of Obesity (EASO) now positions incretin-based therapies (like semaglutide and tirzepatide) as the primary pharmacological approach to obesity treatment.
* First-Line Options: Tirzepatide and semaglutide are recommended as first-line treatments for obesity and many of its complications.
* Semaglutide’s Potential: The phase 3 ESSENCE trial (published after the algorithm’s cutoff date) suggests semaglutide may soon be added as a first-line option.
* Alternative Options: Liraglutide or naltrexone-bupropion can be considered when less important weight loss is the goal.
* Individualized Treatment: The framework stresses that treatment must be tailored to each patient, considering clinical factors (degree of adiposity, complications, comorbidities, concurrent therapies) and social/personal factors (socioeconomic status, patient values, goals).
* Cost Considerations: The framework acknowledges the economic impact of widespread incretin use but argues that the long-term costs of untreated obesity (cardiovascular disease, diabetes, etc.) should be equally considered in policy and payer decisions.
* Regular Updates: EASO plans to update the treatment algorithm regularly to incorporate new evidence as it emerges.

References Cited:

  1. McGowan B,Ciudin A,baker JL,et al. Framework for the pharmacological treatment of obesity and its complications from the European Association for the study of Obesity (EASO). Night with. Published online october 2, 2025. doi:10.1038/s41591-025-03765-w
  2. Semaglutide and tirzepatide recommended as first-line treatment of obesity and most of its complications in ne (The sentence is incomplete in the provided text).

Let me know if you’d like me to elaborate on any specific aspect of this information!